Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Delayed NYSE			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

09-17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
09-15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI

Market Cap	63.66B 56.73B 52.52B 47.53B 89.54B 6,007B 90.61B 630B 247B 3,158B 239B 234B 10,062B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 72.15B 66.8B 60.45B 114B 7,640B 115B 801B 314B 4,016B 304B 297B 12,797B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

09-17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
09-15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI
09-01	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25/09/25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
19/08/25	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
30/06/25	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
12/02/25	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Allergan plc Stock

Stocks

AGN

IE00BY9D5467

Pharmaceuticals

Valuation: Allergan plc

Latest news: Allergan plc

Press Releases: Allergan plc

News in other languages: Allergan plc

Managers and Directors: Allergan plc

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

10-21	Allergan Aesthetics présente ses dernières avancées scientifiques
20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...

Director	Title	Age	Since
Scott Reents BRD	Director/Board Member	-	08/05/2020
Ryan Quigley BRD	Director/Board Member	-	08/05/2020
Andres Rodrigo BRD	Director/Board Member	-	08/05/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/8/20 A	James D'Arecca	Issuer sale	Controller/Auditor	19,495	0.0059%
5/8/20 A	Adriane Brown	Issuer sale	Director	2,916	0.0009%
5/8/20 A	Matthew Walsh	Issuer sale	Chief Financial Officer	67,678	0.0206%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLERGAN PLC	-.--%	+1.73%	-	-	63.66B
ELI LILLY AND COMPANY	-1.01%	+8.94%	+57.08%	+117.36%	1,144B
JOHNSON & JOHNSON	-0.61%	+3.69%	+33.07%	+68.48%	625B
ABBVIE INC.	-1.48%	+3.81%	+22.73%	+94.76%	511B
ROCHE HOLDING AG	+0.54%	+8.95%	+39.45%	+64.02%	377B
MERCK & CO., INC.	+1.07%	+5.56%	+73.63%	+45.98%	366B
NOVARTIS AG	+0.30%	+6.35%	+21.84%	+49.62%	291B
ASTRAZENECA PLC	-0.03%	+6.04%	+0.40%	+20.94%	262B
AMGEN INC.	-0.14%	+6.18%	+44.51%	+57.22%	237B
GILEAD SCIENCES, INC.	-1.88%	+3.82%	+24.74%	+97.39%	194B
Average	-0.03%	+5.85%	+35.27%	+68.42%	407.16B
Weighted average by Cap.	+0.33%	+6.83%	+40.23%	+79.57%

	2018	2019
Net sales	15.79B 14.07B 13.02B 11.79B 22.21B 1,490B 22.47B 156B 61.28B 783B 59.22B 57.99B 2,495B	16.09B 14.34B 13.27B 12.01B 22.63B 1,518B 22.9B 159B 62.45B 798B 60.35B 59.1B 2,543B
Net income	-5.1B -4.54B -4.2B -3.81B -7.17B -481B -7.25B -50.41B -19.78B -253B -19.12B -18.72B -806B	-5.27B -4.7B -4.35B -3.94B -7.41B -497B -7.5B -52.14B -20.46B -261B -19.77B -19.36B -833B
Net Debt	21.89B 19.51B 18.06B 16.34B 30.79B 2,066B 31.16B 217B 84.96B 1,086B 82.12B 80.41B 3,460B	17.3B 15.42B 14.28B 12.92B 24.34B 1,633B 24.63B 171B 67.16B 858B 64.91B 63.56B 2,735B